Abstract
Cardiovascular disease is the most prevalent cause of death in patients with chronic kidney disease (CKD), even at an early stage of the disease and is considered a coronary heart disease risk equivalent. Therefore, therapeutic efforts to control modifiable additional cardiovascular risk factors such as dyslipidemia in this population seems reasonable. Indeed, abnormalities of lipid metabolism are often encountered in patients with CKD, end stage renal disease or after kidney transplantation. In this review we will summarize the currently available data on etiology, epidemiology, and impact on cardiovascular morbidity in patients with CKD, renal pathologies like the nephrotic syndrome and after kidney transplantation and give a brief overview of the existing guidelines on treating dyslipidemia.
Keywords: Dyslipidemia, chronic kidney disease, cardiovascular risk, statin, etiology, urinalysis, nephropathy, hematuria, glycaemia, acetosalicylic acid, polysulfone, unequivocally, lipiduria, tubulointerstitial, mesangioproliferative, rapamycin, mycophenolate, calcineurin, sirolimus
Current Pharmaceutical Design
Title: Dyslipidemia Treatment and Cardiovascular Disease in the Renal Patient
Volume: 17 Issue: 9
Author(s): Volker Burst and Thomas Benzing
Affiliation:
Keywords: Dyslipidemia, chronic kidney disease, cardiovascular risk, statin, etiology, urinalysis, nephropathy, hematuria, glycaemia, acetosalicylic acid, polysulfone, unequivocally, lipiduria, tubulointerstitial, mesangioproliferative, rapamycin, mycophenolate, calcineurin, sirolimus
Abstract: Cardiovascular disease is the most prevalent cause of death in patients with chronic kidney disease (CKD), even at an early stage of the disease and is considered a coronary heart disease risk equivalent. Therefore, therapeutic efforts to control modifiable additional cardiovascular risk factors such as dyslipidemia in this population seems reasonable. Indeed, abnormalities of lipid metabolism are often encountered in patients with CKD, end stage renal disease or after kidney transplantation. In this review we will summarize the currently available data on etiology, epidemiology, and impact on cardiovascular morbidity in patients with CKD, renal pathologies like the nephrotic syndrome and after kidney transplantation and give a brief overview of the existing guidelines on treating dyslipidemia.
Export Options
About this article
Cite this article as:
Burst Volker and Benzing Thomas, Dyslipidemia Treatment and Cardiovascular Disease in the Renal Patient, Current Pharmaceutical Design 2011; 17 (9) . https://dx.doi.org/10.2174/138161211795428867
DOI https://dx.doi.org/10.2174/138161211795428867 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Graphical Abstracts
Letters in Drug Design & Discovery Overview and Developments Regarding Functional Foods and Beverages
Current Nutrition & Food Science Management of Hypertension in Relation to Acute Coronary Syndromes and Revascularisation
Current Pharmaceutical Design Hypertension and Compliance to Treatment in the Primary Care Setting: Key Issues from the Literature Review
Current Hypertension Reviews Premature Ageing Prevention: Limitations and Perspectives of Pharmacological Interventions
Current Drug Targets Signs and Related Mechanisms of Ethanol Hepatotoxicity
Current Drug Abuse Reviews Polyphenols: A Diverse Class of Multi-Target Anti-HIV-1 Agents
Current Drug Metabolism Vitamin D in Atherosclerosis, Vascular Disease, and Endothelial Function
Current Drug Targets Recent Advances in the Synthesis and Anticancer Activity of Some Molecules Other Than Nitrogen Containing Heterocyclic Moeities
Mini-Reviews in Medicinal Chemistry Beta-Blockers for the Treatment of Essential Hypertension: What are the Arguments Against Their Use as First Line Therapy?
Current Hypertension Reviews DYRK1A: A Potential Drug Target for Multiple Down Syndrome Neuropathologies
CNS & Neurological Disorders - Drug Targets Can Marine Omega 3 Fatty Acids Prevent and/or Treat Metabolic Syndrome?
Current Nutrition & Food Science Is Peri-Operative Isolated Systolic Hypertension (ISH) a Cardiac Risk Factor?
Current Cardiology Reviews Macrophage Polarization as a Therapeutic Target in Myocardial Infarction
Current Drug Targets Combining Diffusion-Weighted Imaging Patterns with ABCD2 Score Predicts Stroke Risk after Transient Ischemic Attack
Current Neurovascular Research Blood Serum Atherogenicity: Cellular Test for the Development of Anti- Atherosclerotic Therapy
Current Pharmaceutical Design Genetic Interactions Effects of Cardiovascular Disorder Using Computational Models: A Review
Current Biotechnology Statins and Cancer
Anti-Cancer Agents in Medicinal Chemistry Pathophysiology of Diabetic Dyslipidaemia
Current Vascular Pharmacology Markers of Arrhythmogenic Risk in Hypertensive Subjects
Current Pharmaceutical Design